[
  {
    "ts": null,
    "headline": "This Invesco ETF Pays a 4.71% Yield With 50 Low-Volatility Dividend Stocks (3x the S&P 500)",
    "summary": "Invesco High Dividend Low Volatility ETF (NYSEARCA:SPHD) generates its 4.71% yield – roughly three times the S&P 500’s current dividend – by holding a concentrated portfolio of 50 U.S. stocks selected for high dividend yields and low volatility. With $3.1 billion in assets and a reasonable 0.30% expense ratio, SPHD takes an equal-weight approach to ... This Invesco ETF Pays a 4.71% Yield With 50 Low-Volatility Dividend Stocks (3x the S&P 500)",
    "url": "https://finnhub.io/api/news?id=5ed99d63657d990288c3db232366636ae6d6c77730e8f9b1c24d05f43f225d88",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765385271,
      "headline": "This Invesco ETF Pays a 4.71% Yield With 50 Low-Volatility Dividend Stocks (3x the S&P 500)",
      "id": 137750196,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Invesco High Dividend Low Volatility ETF (NYSEARCA:SPHD) generates its 4.71% yield – roughly three times the S&P 500’s current dividend – by holding a concentrated portfolio of 50 U.S. stocks selected for high dividend yields and low volatility. With $3.1 billion in assets and a reasonable 0.30% expense ratio, SPHD takes an equal-weight approach to ... This Invesco ETF Pays a 4.71% Yield With 50 Low-Volatility Dividend Stocks (3x the S&P 500)",
      "url": "https://finnhub.io/api/news?id=5ed99d63657d990288c3db232366636ae6d6c77730e8f9b1c24d05f43f225d88"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) Announces Results from the Phase 3 BASIS Study Evaluating HYMPAVZI",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the best pharma stocks to invest in. Pfizer Inc. (NYSE:PFE) announced on December 6 results from the Phase 3 BASIS study evaluating HYMPAVZI for adults and adolescents living with hemophilia A or B with inhibitors. The results showed the superiority of HYMPAVZI for the improvement of bleeding outcomes in comparison […]",
    "url": "https://finnhub.io/api/news?id=cba8d9e30d302c40ef1387d50d3ff06d598093fa35efb2bc42b8230cc294075f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765384123,
      "headline": "Pfizer Inc. (PFE) Announces Results from the Phase 3 BASIS Study Evaluating HYMPAVZI",
      "id": 137750320,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the best pharma stocks to invest in. Pfizer Inc. (NYSE:PFE) announced on December 6 results from the Phase 3 BASIS study evaluating HYMPAVZI for adults and adolescents living with hemophilia A or B with inhibitors. The results showed the superiority of HYMPAVZI for the improvement of bleeding outcomes in comparison […]",
      "url": "https://finnhub.io/api/news?id=cba8d9e30d302c40ef1387d50d3ff06d598093fa35efb2bc42b8230cc294075f"
    }
  },
  {
    "ts": null,
    "headline": "TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer",
    "summary": "NEW YORK, December 10, 2025--Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA® (tucatinib) as part of an investigational first-line maintenance treatment combination, following chemotherapy-based induction, in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). The primary endpoint analysis showed a 35.9% reduction in the risk of disease progression or death amo",
    "url": "https://finnhub.io/api/news?id=5cf7752321e2959b828706a9dbe61b88c7d26dbb2e7553aaa9b04e5bc8eb20e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765372500,
      "headline": "TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer",
      "id": 137750321,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, December 10, 2025--Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA® (tucatinib) as part of an investigational first-line maintenance treatment combination, following chemotherapy-based induction, in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). The primary endpoint analysis showed a 35.9% reduction in the risk of disease progression or death amo",
      "url": "https://finnhub.io/api/news?id=5cf7752321e2959b828706a9dbe61b88c7d26dbb2e7553aaa9b04e5bc8eb20e6"
    }
  },
  {
    "ts": null,
    "headline": "PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence",
    "summary": "Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.",
    "url": "https://finnhub.io/api/news?id=c5951110279522e0c97ea2cd7f2fb0de73510d3aa02f717d2eb22d2782cd32ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765370580,
      "headline": "PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence",
      "id": 137749825,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.",
      "url": "https://finnhub.io/api/news?id=c5951110279522e0c97ea2cd7f2fb0de73510d3aa02f717d2eb22d2782cd32ed"
    }
  },
  {
    "ts": null,
    "headline": "JNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment Now?",
    "summary": "JNJ and PFE battle patent cliffs and policy headwinds, but rising estimates and stronger 2025 momentum push JNJ ahead in this blue-chip faceoff.",
    "url": "https://finnhub.io/api/news?id=1381ba816a9fbdf0f7caa089d7eb1c2f8328135096e66fb763969c39e53e70fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765369860,
      "headline": "JNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment Now?",
      "id": 137749866,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "JNJ and PFE battle patent cliffs and policy headwinds, but rising estimates and stronger 2025 momentum push JNJ ahead in this blue-chip faceoff.",
      "url": "https://finnhub.io/api/news?id=1381ba816a9fbdf0f7caa089d7eb1c2f8328135096e66fb763969c39e53e70fd"
    }
  },
  {
    "ts": null,
    "headline": "The Fed’s Divided on Rates. Why Stock Markets Can Rise Through 2026 Anyway and 5 Other Things to Know Today.",
    "summary": "What a SpaceX IPO could mean for Tesla shareholders, Pfizer pursuing next weight-loss drug in Chinese labs, more news to start your day.",
    "url": "https://finnhub.io/api/news?id=9b7e41b95884a28078fcbe4c51422971730ef1cb103689605a7ae06dfc7e96de",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765365960,
      "headline": "The Fed’s Divided on Rates. Why Stock Markets Can Rise Through 2026 Anyway and 5 Other Things to Know Today.",
      "id": 137749798,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "What a SpaceX IPO could mean for Tesla shareholders, Pfizer pursuing next weight-loss drug in Chinese labs, more news to start your day.",
      "url": "https://finnhub.io/api/news?id=9b7e41b95884a28078fcbe4c51422971730ef1cb103689605a7ae06dfc7e96de"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca: A Rare Compound Growth Opportunity In Biopharma",
    "summary": "AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about AZN stock here.",
    "url": "https://finnhub.io/api/news?id=7607e031783e690b2011e6797309b77b7a7084aa1403fc9ee0fe0c21f814be29",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765362409,
      "headline": "AstraZeneca: A Rare Compound Growth Opportunity In Biopharma",
      "id": 137747724,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307043297/image_1307043297.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about AZN stock here.",
      "url": "https://finnhub.io/api/news?id=7607e031783e690b2011e6797309b77b7a7084aa1403fc9ee0fe0c21f814be29"
    }
  },
  {
    "ts": null,
    "headline": "China's Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer",
    "summary": "US pharmaceutical behemoth Pfizer has agreed to pay up to US$2.1 billion to Shanghai-based Fosun Pharma's unit Yao Pharma for an experimental oral obesity drug, underscoring the growing trend of Chinese drug makers selling early-stage assets to global multinationals. Under the licensing agreement, Yao Pharma would grant Pfizer an exclusive worldwide licence for the development, use, manufacturing and commercialisation of oral small-molecule drugs known as GLP-1 receptor agonists, including YP050",
    "url": "https://finnhub.io/api/news?id=701171b3f0cb112052a3cc2baae99d53e3c380d6abf5955fae89c5ae952cdc52",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765359000,
      "headline": "China's Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer",
      "id": 137749828,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "US pharmaceutical behemoth Pfizer has agreed to pay up to US$2.1 billion to Shanghai-based Fosun Pharma's unit Yao Pharma for an experimental oral obesity drug, underscoring the growing trend of Chinese drug makers selling early-stage assets to global multinationals. Under the licensing agreement, Yao Pharma would grant Pfizer an exclusive worldwide licence for the development, use, manufacturing and commercialisation of oral small-molecule drugs known as GLP-1 receptor agonists, including YP050",
      "url": "https://finnhub.io/api/news?id=701171b3f0cb112052a3cc2baae99d53e3c380d6abf5955fae89c5ae952cdc52"
    }
  },
  {
    "ts": null,
    "headline": "The Fed meeting, pressure on Oracle, Target's fashion-forward renovation and more in Morning Squawk",
    "summary": "Here are five key things investors need to know to start the trading day.",
    "url": "https://finnhub.io/api/news?id=94201dd50dfa8a410879a0315099aaa24a98694add1d31412bc1d2725be05fad",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765353820,
      "headline": "The Fed meeting, pressure on Oracle, Target's fashion-forward renovation and more in Morning Squawk",
      "id": 137748288,
      "image": "https://image.cnbcfm.com/api/v1/image/108219013-1761772288767-gettyimages-2243505194-POWELL_FOMC_NYSE.jpeg?v=1765331525&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "Here are five key things investors need to know to start the trading day.",
      "url": "https://finnhub.io/api/news?id=94201dd50dfa8a410879a0315099aaa24a98694add1d31412bc1d2725be05fad"
    }
  }
]